uniQure Stock Rises 12% in Early Trade
uniQure N.V. shares eased in pre-market trading Thursday, trimming part of Wednesday’s 11.7% jump as traders moved around the Dutch biotech’s uncertain Huntington’s disease gene therapy outlook. The stock ended at $29.88 in the prior session and changed hands at $29.40 ahead of the Nasdaq open at 8:00 a.m. EDT. QURE now trades mostly as a play on AMT-130, its main program for Huntington’s disease. The disease is fatal and inherited. uniQure has been telling investors it plans to file for UK marketing authorization—a request to sell the drug—in the third quarter of 2026, and is also looking for more guidance from U.S. regulators.